Deferasirox    (DrugBank: Deferasirox)

3 diseases
IDDisease name (Link within this page)Number of trials
254Porphyria2
284Diamond-Blackfan anemia3
286Hereditary sideroblastic anemia4

254. Porphyria    [ 59 clinical trials,   52 drugs,   (DrugBank: 17 drugs),   17 drug target genes,   33 drug target pathways]
Searched query = "Porphyria", "CEP", "Erythropoietic protoporphyria", "EPP", "X-linked dominant protoporphyria", "XLDP", "PCT", "HEP", "AIP", "ADP", "VP", "Hereditary coproporphyria", "HCP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 59 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01284946
(ClinicalTrials.gov)
January 201126/1/2011Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea TardaA Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron OverloadPorphyria Cutanea TardaDrug: ExjadeAssistance Publique - Hôpitaux de ParisAssociation pour l'Etude des Fonctions Digestives (AEFD)Recruiting18 YearsN/ABoth45Phase 2France
2NCT00599326
(ClinicalTrials.gov)
January 200810/1/2008Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea TardaPilot Trial of Deferasirox in the Treatment of Porphyria Cutanea TardaPorphyria Cutanea TardaDrug: DeferasiroxUniversity of Texas Southwestern Medical CenterNovartis PharmaceuticalsCompleted18 YearsN/AAll10Phase 3United States

284. Diamond-Blackfan anemia    [ 37 clinical trials,   110 drugs,   (DrugBank: 34 drugs),   22 drug target genes,   121 drug target pathways]
Searched query = "Diamond-Blackfan anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 37 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-000766-20-GB
(EUCTR)
17/07/200813/12/2007A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIAA multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIA Beta-thalassemia major (TM) or Diamond Blackfan anemia (DBA) or myelodysplastic syndromes (MDS) (low and INT-1 risk as per the IPSS for MDS) or sideroblastic anemia and myocardial iron overload as indicated by a T2* =6 but not greater than 20 ms, with no symptoms of cardiac dysfunction, and an MRI measured LVEF =56%.Novartis Pharma Services AGNULLNot Recruiting Female: yes
Male: yes
192Phase 2Italy;United Kingdom
2NCT00673608
(ClinicalTrials.gov)
November 20075/5/2008Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadA Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study)Hemoglobinopathies;Myelodysplastic Syndromes;Other Inherited or Acquired Anaemia;MPD Syndrome;Diamond-Blackfan Anemia;Other Rare Anaemias;Transfusional Iron OverloadDrug: deferasiroxNovartisNULLCompleted18 YearsN/AAll118Phase 4Australia
3NCT00235391
(ClinicalTrials.gov)
October 20056/10/2005Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadA Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron ChelatorsThalassemia;Sickle Cell Disease;Diamond Blackfan Anemia;MyelofibrosisDrug: DeferasiroxNovartis PharmaceuticalsNULLCompleted2 YearsN/AAll1683Phase 3United States;Belgium;Canada;Germany;Greece;Italy;Netherlands;Spain;Taiwan;Thailand;Turkey;United Kingdom;Australia

286. Hereditary sideroblastic anemia    [ 6 clinical trials,   13 drugs,   (DrugBank: 5 drugs),   0 drug target gene,   0 drug target pathway]
Searched query = "Hereditary sideroblastic anemia", "Congenital sideroblastic anemia", "Sideroblastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-021062-29-GR
(EUCTR)
12/04/201102/02/2011Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIONPhase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload
MedDRA version: 13.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Desferal
Product Name: deferoxamine
Product Code: DFO
INN or Proposed INN: DEFEROXAMINE MESILATE
Trade Name: DESFERAL
Product Name: deferoxamine
Product Code: DFO
INN or Proposed INN: DEFEROXAMINE MESILATE
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
45Phase 2Greece;Italy;United Kingdom
2EUCTR2010-021062-29-IT
(EUCTR)
30/12/201029/11/2010Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIONPhase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION Transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload
MedDRA version: 9.1;Level: LLT;Classification code 10043392
Trade Name: EXJADE
INN or Proposed INN: DEFERASIROX
Trade Name: EXJADE
INN or Proposed INN: DEFERASIROX
Trade Name: EXJADE
INN or Proposed INN: DEFERASIROX
Trade Name: DESFERAL
INN or Proposed INN: Deferoxamine
Trade Name: DESFERAL
INN or Proposed INN: Deferoxamine
NOVARTIS FARMANULLNot RecruitingFemale: yes
Male: yes
45Phase 2Greece;United Kingdom;Italy
3EUCTR2010-021062-29-GB
(EUCTR)
21/12/201020/10/2010Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIONPhase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload
MedDRA version: 14.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Product Name: deferoxamine
Product Code: DFO
INN or Proposed INN: DEFEROXAMINE MESILATE
Product Name: deferoxamine
Product Code: DFO
INN or Proposed INN: DEFEROXAMINE MESILATE
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: deferasirox
INN or Proposed INN: deferasirox
INN or Proposed INN: deferasirox
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
45Phase 2Greece;Italy;United Kingdom
4EUCTR2007-000766-20-GB
(EUCTR)
17/07/200813/12/2007A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIAA multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIA Beta-thalassemia major (TM) or Diamond Blackfan anemia (DBA) or myelodysplastic syndromes (MDS) (low and INT-1 risk as per the IPSS for MDS) or sideroblastic anemia and myocardial iron overload as indicated by a T2* =6 but not greater than 20 ms, with no symptoms of cardiac dysfunction, and an MRI measured LVEF =56%.Novartis Pharma Services AGNULLNot Recruiting Female: yes
Male: yes
192Phase 2Italy;United Kingdom